Physician profile
Peter A Scheidler
NPI 1538142310
$190,421.56
in general payments reported to CMS, 2019-2025
62 companies · $32K in 2025
The $32K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,532 · 2020: $7,083 · 2021: $8,152 · 2022: $27K · 2023: $81K · 2024: $31K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $126K · Travel and Lodging: $9,732 · Food and Beverage: $8,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125,700.00 |
| Travel and Lodging | $9,731.50 |
| Food and Beverage | $8,889.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $161,642.88 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $9,653.92 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Allergan, INC. | $7,977.45 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $1,787.38 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $1,563.98 | 2019-2022 | |
| Novo Nordisk INC | $1,227.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $894.28 | 2019-2025 | |
| Antares Pharma, INC. | $863.90 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Corcept Therapeutics | $661.53 | 2019-2024 | Korlym |
| Lilly USA, LLC | $386.75 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.07 | 2019-2025 | Jardiance, Synjardy |
| Astellas Pharma US INC | $255.05 | 2020-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $217.42 | 2021-2025 | Rexulti |
| Amarin Pharma, INC. | $186.25 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $168.10 | 2019-2020 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $160.93 | 2021 | |
| Merck Sharp & Dohme LLC | $158.61 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Vanda Pharmaceuticals INC. | $153.86 | 2024-2025 | Hetlioz, Fanapt |
| Glaxosmithkline, LLC. | $131.97 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Xeris Pharmaceuticals, INC. | $126.24 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Boston Scientific Corporation | $124.28 | 2019 | |
| Genzyme Corporation | $119.94 | 2025 | |
| Ucb, INC. | $93.69 | 2021-2022 | |
| Ibsa Pharma INC. | $92.36 | 2021-2023 | Tirosint, Licart |
| Supernus Pharmaceuticals, INC. | $89.24 | 2019-2020 | Xyosted |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.48 | 2019-2023 | Xifaxan |
| Axsome Therapeutics, INC. | $79.87 | 2025 | Auvelity, Sunosi |
| Alkermes, INC. | $74.39 | 2022-2024 | Vivitrol, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $71.48 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.07 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.01 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $68.65 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $68.48 | 2019-2021 | |
| Exact Sciences Corporation | $62.54 | 2023-2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $60.59 | 2020-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $55.93 | 2023-2024 | Inpefa |
| Medtronic, INC. | $46.86 | 2022-2023 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Lundbeck LLC | $43.86 | 2024-2025 | Rexulti |
| Daiichi Sankyo INC. | $43.53 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $40.91 | 2023 | Quviviq |
| Nestle Healthcare Nutrition INC. | $32.28 | 2021 | |
| Radius Health, INC. | $31.09 | 2024-2025 | Tymlos |
| Qol Medical, LLC | $30.05 | 2021 | |
| Phathom Pharmaceuticals, INC. | $29.30 | 2024 | Voquezna |
| Halozyme INC | $29.22 | 2023 | |
| Insulet Corporation | $28.31 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $28.17 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.54 | 2025 | Caplyta |
| Amneal Pharmaceuticals LLC | $23.44 | 2025 | Unithroid |
| Amphastar Pharmaceuticals, INC. | $23.22 | 2025 | |
| Abbott Laboratories | $20.71 | 2022 | |
| Phadia US INC. | $16.42 | 2023 | Immunocap |
| Vivus LLC | $16.16 | 2024 | Pancreaze |
| Organogenesis INC. | $15.60 | 2022 | |
| Axonics, INC. | $14.67 | 2024 | Axonics |
| Grifols USA, LLC | $14.62 | 2024 | Prolastin-C Liquid |
| Dexcom, INC. | $12.80 | 2023 | Dexcom G6 Transmitter |
| Aytu Biopharma, INC. | $12.74 | 2019 | |
| Alfasigma USA, INC. | $12.08 | 2021 | |
| Renalytix Ai, INC. | $12.02 | 2022 | |
| Bardy Diagnostics, INC. | $11.82 | 2022 | |
| Eisai INC. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Scheidler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.